Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORACLE long-term follow-up of GT005 in geographic atrophy secondary to age-related macular degeneration
NL-OMON56154Phase 2Withdrawn
- Sponsor
- Gyroscope Therapeutics
- Start
- Dec 2022
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GT005 in age-related macular degeneration (AMD), sponsored by Gyroscope Therapeutics. Primary endpoint: Long-term safety of GT005. Planned start Dec 2022; status: withdrawn.
02
Drugs
GT005
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON56154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56154.